CytoSorbents Announces Leadership Appointment
CytoSorbents Corporation (NASDAQ: CTSO) has taken a significant step forward by appointing Melanie Grossman, CPA, as Vice President and Corporate Controller. With a career spanning 25 years in finance and accounting within global, publicly-traded companies, Ms. Grossman is poised to bring a wealth of expertise to the team at CytoSorbents.
Experience and Value Addition
Melanie Grossman comes to CytoSorbents from her role as Senior Vice President and Group Controller at Staffing 360. Her journey has included roles such as Director of Finance and Accounting for Vaxxinity and Controller for Byram Healthcare, alongside extensive experience at Stryker Orthopedic. Starting her career in public accounting with Ernst & Young, Melanie has cultivated significant knowledge and skills in managing financial operations and regulatory compliance.
Peter J. Mariani, Chief Financial Officer of CytoSorbents, expressed confidence in Melanie's ability to enhance the company's financial frameworks, stating, "Her extensive expertise in financial operations and internal controls will be invaluable as we continue driving growth and efficiencies in our core business. This leadership will support our readiness for the potential launch of DrugSorb™-ATR in the U.S. and beyond."
Compensation Under Nasdaq Rules
In association with Melanie's appointment, the Compensation Committee of the Board of Directors approved several inducement awards, which comply with Nasdaq Listing Rule 5635(c)(4). These awards will include:
- Non-Qualified Stock Options to purchase a total of 25,000 shares of common stock, vesting in increments over three years.
- Signing Restricted Stock Units of 35,000 units, vesting upon certain conditions related to company control.
- Change-of-Control Restricted Stock Units of 35,000 units, which will activate under specified change-of-control conditions.
The vesting terms of each award are contingent on continued service as outlined in the applicable agreements.
About CytoSorbents Corporation
CytoSorbents Corporation is recognized as a leader in critical care and cardiac surgery blood purification technologies. Their products are focused on treating life-threatening conditions through advanced blood purification solutions. CytoSorbents' proprietary technology employs highly porous polymer beads capable of effectively removing harmful substances from blood.
Currently, over 270,000 devices have been utilized worldwide, showcasing CytoSorb's innovative approach to addressing severe health conditions associated with inflammation, organ failure, and other critical ailments. The technology is particularly effective in managing blood thinners during surgeries to minimize bleeding risks and treating patients suffering from severe inflammatory conditions.
Continued Innovation and Regulatory Progress
The company is actively advancing its DrugSorb™-ATR system designed to minimize perioperative bleeding for patients taking anticoagulants during surgeries. CytoSorbents' leadership maintains an ambitious pipeline that includes efforts for FDA approvals and market expansions of their products, underscoring their commitment to improving patient outcomes in critical care settings.
For more details, individuals can visit CytoSorbents' official site, where they provide comprehensive information about their product offerings and ongoing developments in the field of blood purification.
Frequently Asked Questions
What is the significance of Melanie Grossman’s appointment?
Melanie Grossman brings over 25 years of experience to CytoSorbents, enhancing the company’s financial operations and strategic growth initiatives.
What roles has Melanie Grossman held prior to joining CytoSorbents?
Prior to her appointment, she served as Senior Vice President and Group Controller at Staffing 360, and has held various financial leadership positions in other organizations.
What are the inducement awards mentioned in the appointment announcement?
These include stock options and restricted stock units as part of Ms. Grossman’s compensation package, under Nasdaq's regulations.
What technologies does CytoSorbents develop?
CytoSorbents focuses on blood purification technologies aimed at treating critical conditions such as sepsis, trauma, and cardiac complications.
How does CytoSorbents plan to expand its market presence?
Through innovative products like DrugSorb™-ATR and ongoing regulatory submissions, CytoSorbents aims to broaden its therapeutic offerings in the U.S. and globally.
